Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Instil Bio, Inc.NASDAQ: TIL

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $4.2M (cash outflow) fell 85.1% year over year, behind the -39.3% change in trailing-twelve-month net income. Sequentially, it fell 48.7% from the prior quarter. Over 3 fiscal years it compounded at -31.6% a year.

Context

  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$7.8M (-89.1%) for the fiscal year ending Dec 2026, a slowdown from the -3.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.2M-48.7% QoQ
Last fiscal yearDec 2025
-$71.37M-3.7% YoY
LTMMar 2026
-$47.38M-39.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.1%-88.9%-3.8 pp
1 year-3.7%-89.1%-85.3 pp
3-year CAGR-31.6%+1.1%+32.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(71.37M) USD
Year-over-year change
+3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.3% is the 6th highest of 9, against a peer median of -18.6%.
  • Over three fiscal years its annual growth of -31.6% compares with a peer median of -4.0%.
TIL Competitors
Net Income for TIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRZNSurrozen, Inc.LTM Mar 2026$342.56M USD+319.3%+88.7%4571.1%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$124.13M USD-44.6%-16.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$113.22M USD-48.4%+6.6%—
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M USD-29.4%-21.8%4987.4%
TILInstil Bio, Inc.LTM Mar 2026$47.38M USD-39.3%-31.6%—
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$35.52M CAD+12.8%+16.7%—
WHWKWhitehawk Therapeutics IncLTM Dec 2025$20.6M USD-67.7%-30.2%288.3%
Peer median (excluding TIL) —-18.6%-4.0%4571.1%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(156.79M)(223.18M)(156.09M)(74.14M)(71.37M)
Depreciation & Amortization2.75M5.99M4.76M3.61M534K
Deferred Income Tax710K0000
Stock-Based Compensation26.2M30.44M18.17M17.26M8.69M
Change in Working Capital4.36M(9.57M)(9.02M)(12.61M)(560K)
Accounts Receivables0000(3.4M)
Inventory00000
Accounts Payables3.86M(1.81M)(1.13M)(556K)116K
Other Working Capital499K(7.76M)(7.89M)(12.05M)2.72M
Other Non-Cash Items636K16.15M60.15M10.18M26.09M
Operating Cash Flow(122.14M)(180.16M)(82.03M)(55.7M)(36.62M)
Capital Expenditures(57.83M)(84.59M)(20.66M)(10M)0
Acquisitions (Net)01.17M00432K
Purchases of Investments(1.11B)(666.22M)(301.47M)(135.6M)(100.86M)
Sales of Investments691M865.35M361.7M198.71M135.9M
Other Investing Activities0(1.17M)1.56M866K0
Investing Cash Flow(474.4M)114.54M41.13M53.97M25.48M
Debt Repayment070.34M8.08M2.76M6.61M
Common Stock Issued339.02M1.55M00853K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.69M00(1.01M)(172K)
Financing Cash Flow393.16M71.89M8.08M1.76M7.29M
Effect of Forex Changes(304K)(637K)(201K)(94K)20K
Net Change in Cash(203.67M)5.63M(33.02M)(61K)(3.83M)
Free Cash Flow(179.97M)(264.75M)(102.69M)(65.7M)(36.62M)

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.